These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 6171962)

  • 21. [The probenecid test and its application to research in schizophrenia].
    Chen YF
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1984 Aug; 17(4):252-5. PubMed ID: 6085620
    [No Abstract]   [Full Text] [Related]  

  • 22. Nongenetic factors affecting human platelet monoamine oxidase [proceedings].
    Friedhoff AJ; Miller JC
    Psychopharmacol Bull; 1981 Jan; 17(1):101-3. PubMed ID: 6112772
    [No Abstract]   [Full Text] [Related]  

  • 23. [Prognosis of the effectiveness of pharmacotherapy of patients with acute schizophrenia based on a correlation and regression analysis of clinical and electroencephalographic indices].
    Nemtsov AV; Kalinin VV; Zaĭtsev SG; Golikova TI
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1982 Sep; 82(9):68-73. PubMed ID: 6128846
    [No Abstract]   [Full Text] [Related]  

  • 24. Clozapine therapy and increases in homovanillic acid.
    Risch SC
    Arch Gen Psychiatry; 1995 Mar; 52(3):244. PubMed ID: 7532936
    [No Abstract]   [Full Text] [Related]  

  • 25. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia.
    Revicki DA
    J Psychiatry Neurosci; 1997 Jul; 22(4):256-66. PubMed ID: 9262048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The psychophysiology of schizophrenia (author's transl)].
    Venables PH
    Nervenarzt; 1978 Nov; 49(11):625-33. PubMed ID: 31574
    [No Abstract]   [Full Text] [Related]  

  • 27. Catechol-O-methyltransferase and monoamine oxidase A genotypes and drug response to conventional neuroleptics in schizophrenia.
    Illi A; Mattila KM; Kampman O; Anttila S; Roivas M; Lehtimäki T; Leinonen E
    J Clin Psychopharmacol; 2003 Oct; 23(5):429-34. PubMed ID: 14520117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebrospinal fluid probenecid studies: a reinterpretation.
    Cowdry RW; Ebert MH; van Kammen DP; Post RM; Goodwin FK
    Biol Psychiatry; 1983 Nov; 18(11):1287-99. PubMed ID: 6197100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short- and long-term effects of GABA and dopamine neurons during treatment with sulpiride.
    Zimmer R; Teelken AW; Cramer H; Ackenheil M; Zander KJ; Fischer H
    Adv Biochem Psychopharmacol; 1980; 24():537-9. PubMed ID: 6250324
    [No Abstract]   [Full Text] [Related]  

  • 30. Plasma prolactin and plasma homovanillic acid: predictors of clinical response in schizophrenia.
    Davila R; Gonzalez MA; Zumarraga M; Andia I; Guimon J; Silva RR; Friedhoff AJ
    Biol Psychiatry; 1995 Aug; 38(4):267-9. PubMed ID: 8547450
    [No Abstract]   [Full Text] [Related]  

  • 31. [Biological aspects of suicide].
    Linkowski P; Mendlewicz J
    Acta Psychiatr Belg; 1983; 83(1):7-12. PubMed ID: 6193681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Further studies on the mechanism of antipsychotic action: potentiation by alpha-methyltyrosine of thioridazine effects in chronic schizophrenics.
    Carlsson A; Roos BE; Wålinder J; Skott A
    J Neural Transm; 1973; 34(2):125-32. PubMed ID: 4146641
    [No Abstract]   [Full Text] [Related]  

  • 33. Predictors of response to clozapine.
    Lieberman JA; Kane JM; Safferman AZ; Pollack S; Howard A; Szymanski S; Masiar SJ; Kronig MH; Cooper T; Novacenko H
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():126-8. PubMed ID: 7961556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Various achievements of modern neurophysiology in the area of psychiatry (review of the foreign literature)].
    Paniushkina SV
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1981; 81(8):1229-32. PubMed ID: 6118985
    [No Abstract]   [Full Text] [Related]  

  • 35. The evaluation and management of patients with first-episode schizophrenia: a selective, clinical review of diagnosis, treatment, and prognosis.
    Freudenreich O; Holt DJ; Cather C; Goff DC
    Harv Rev Psychiatry; 2007; 15(5):189-211. PubMed ID: 17924256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apomorphine and schizophrenia.
    Johns CA; Levy MI; Davis BM; Mohs RC; Kendler KS; Mathe AA; Trigos G; Horvath TB; Davis KL
    Psychopharmacol Bull; 1984; 20(1):103-7. PubMed ID: 6718635
    [No Abstract]   [Full Text] [Related]  

  • 37. Psychopharmacologic issues in the maintenance treatment of schizophrenia.
    Kane JM; Borenstein M; Woerner M
    Psychopharmacol Bull; 1984; 20(3):423-5. PubMed ID: 6147875
    [No Abstract]   [Full Text] [Related]  

  • 38. The schizophrenia prodrome: a developmentally informed review and update for psychopharmacologic treatment.
    Thomas LE; Woods SW
    Child Adolesc Psychiatr Clin N Am; 2006 Jan; 15(1):109-33. PubMed ID: 16321727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perspective and the measurement of costs and benefits for cost-effectiveness analysis in schizophrenia.
    Meltzer D
    J Clin Psychiatry; 1999; 60 Suppl 3():32-5; discussion 36-7. PubMed ID: 10073375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clozapine improves working memory updating in schizophrenia.
    Galletly CA; Clark CR; McFarlane AC
    Eur Neuropsychopharmacol; 2005 Dec; 15(6):601-8. PubMed ID: 15905072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.